EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk

Oana-Viola Badulescu iD, Dragos Viorel Scripcariu, Minerva Codruta Badescu iD, Manuela Ciocoiu iD, Maria Cristina Vladeanu, Carmen Elena Plesoianu iD, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum, Iris Bararu Bojan

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147845 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Oana-Viola Badulescu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Hemophilia A, Hemorrhage, Cardiovascular Diseases, Fibrinolytic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Navigating through antithrombotic therapy in patients with both hemophilia and cardiovascular pathology presents a complex scenario with inherent challenges and opportunities. The presence of hemophilia, characterized by impaired blood clotting, adds a layer of complexity to the management of cardiovascular conditions requiring antiplatelet therapy and anticoagulation. Striking a delicate balance between the necessity for antithrombotic treatment to prevent cardiovascular events and the heightened risk of severe bleeding in individuals with hemophilia demands a nuanced and carefully considered approach. The challenges revolve around identifying an optimal therapeutic strategy that effectively mitigates cardiovascular risks without exacerbating bleeding tendencies. In hemophilic patients with cardiovascular disease, the decision to use antiplatelet therapy requires careful consideration of the individual’s bleeding risk profile, considering factors such as the severity of hemophilia, history of bleeding episodes, and concurrent medications. The goal is to provide effective antithrombotic treatment while minimizing the potential for excessive bleeding complications. Conventional anticoagulants like warfarin pose difficulties due to their potential to increase the risk of bleeding. On the other hand, emerging options like novel direct oral anticoagulants (DOACs) present an opportunity, offering predictable pharmacokinetics and user-friendly administration. However, a comprehensive exploration of their safety and efficacy in hemophilic patients is imperative. Achieving the right equilibrium between preventing cardiovascular events and minimizing bleeding risk is pivotal in selecting the most effective therapeutic option for individuals with hemophilia and cardiovascular pathology. A multidisciplinary approach, integrating the expertise of hematologists and cardiologists, becomes essential to customize treatments and address the intricacies of this medical challenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemorrhageCardiovascular DiseasesFibrinolytic AgentsHumansAnticoagulantsPlatelet Aggregation InhibitorsRisk Factors

Stichwörter der Autor:innen

PCI in hemophiliaatrial fibrillation in hemophiliacoronary artery diseasehemophilia

Substanzen

Fibrinolytic AgentsAnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.
  • Department of Surgical Sciences, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.
  • Department of Internal Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.

ORCID-Profile: Oana-Viola Badulescu, Minerva Codruta Badescu, Manuela Ciocoiu, Carmen Elena Plesoianu

Zitieren

APA

Badulescu, O. V., Scripcariu, D. V., Badescu, M. C., Ciocoiu, M., Vladeanu, M. C., Plesoianu, C. E., Bojan, A., Iliescu-Halitchi, D., Tudor, R., Huzum, B., & Bararu Bojan, I. (2024). Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147845

Vancouver

Badulescu OV, Scripcariu DV, Badescu MC, Ciocoiu M, Vladeanu MC, Plesoianu CE, et al. Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147845

BibTeX
@article{Badulescu2024,
  author = {Badulescu, Oana-Viola and Scripcariu, Dragos Viorel and Badescu, Minerva Codruta and Ciocoiu, Manuela and Vladeanu, Maria Cristina and Plesoianu, Carmen Elena and Bojan, Andrei and Iliescu-Halitchi, Dan and Tudor, Razvan and Huzum, Bogdan and Bararu Bojan, Iris},
  title = {Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147845}
}
Kostenlos starten →